JAK
Os inibidores de JAK (Janus quinase) são compostos que têm como alvo a via de sinalização JAK-STAT, que está envolvida no crescimento celular, na resposta imunológica e na angiogênese. Ao inibir JAK, esses compostos podem reduzir a sinalização que leva à formação de novos vasos sanguíneos em tumores, inibindo assim o crescimento tumoral. Os inibidores de JAK são importantes no tratamento de cânceres e doenças inflamatórias. Na CymitQuimica, oferecemos uma ampla gama de inibidores de JAK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 245 produtos para "JAK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Londamocitinib
CAS:Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.Fórmula:C28H31F2N7O4SPureza:98.64% - 99.56%Cor e Forma:SolidPeso molecular:599.65Ref: TM-T11706
10mgA consultar25mgA consultar50mgA consultar100mgA consultar1mg170,00€5mg416,00€1mL*10mM (DMSO)537,00€JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Fórmula:C26H36FN5O2Cor e Forma:SolidPeso molecular:469.59Tyk2-IN-10
CAS:Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.Fórmula:C25H27N5O3Cor e Forma:SolidPeso molecular:445.51Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Fórmula:C24H25N7O2Cor e Forma:SolidPeso molecular:443.50GDC-9918
CAS:GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.Fórmula:C20H18F2N6O5SCor e Forma:SolidPeso molecular:492.46YLIU-4-105-1
CAS:YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Fórmula:C32H34F3N7O2Cor e Forma:SolidPeso molecular:605.65Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Fórmula:C19H19F2N7O3Cor e Forma:SolidPeso molecular:431.40CEE321
CAS:CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.Fórmula:C18H16ClN5OCor e Forma:SolidPeso molecular:353.806JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFórmula:C22H17FN6O2SPureza:98%Cor e Forma:SolidPeso molecular:448.47JAK3-IN-18
CAS:JAK3-IN-18 is a selective and orally active dual inhibitor targeting JAK3 and TEC, with IC50 values of 0.5391 nM and 12.40 nM, respectively. It demonstrates remarkable selectivity for AK1, AK2, and TYK2, with selectivity ratios exceeding 10,000-fold. JAK3-IN-18 exhibits exceptional therapeutic efficacy in a mouse model of experimental autoimmune encephalomyelitis and is applicable for multiple sclerosis research.Fórmula:C18H16FN5OPeso molecular:337.35JAK1/TYK2-IN-5
CAS:JAK1/TYK2-IN-5 (compound A1) is an inhibitor of JAK1 and TYK2, exhibiting Ki values of 0.0044 nM for TYK2JH2, 0.02 nM for JAK1 JH2, 6.9 μM for JAK1 JH1, 0.79 μM for JAK2 JH1, 0.21 μM for JAK3 JH1, and 0.55 μM for TYK2JH1. Additionally, it inhibits STAT activation mediated by TYK2/JAK1, induced by IFNα.Fórmula:C26H30N7O4PPeso molecular:535.55CP-352664
CAS:CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Fórmula:C18H18N4Cor e Forma:SolidPeso molecular:290.36iBFAR2
CAS:iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.Fórmula:C19H15F3N2O2Cor e Forma:SolidPeso molecular:360.33TYK2 ligand 2
CAS:TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.Fórmula:C24H20FN7O4Cor e Forma:SolidPeso molecular:489.458Ten01
Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.Fórmula:C18H20F6N4OCor e Forma:SolidPeso molecular:422.37JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Fórmula:C23H22Cl2N4OCor e Forma:SolidPeso molecular:441.35JAK-IN-24
CAS:JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.Fórmula:C20H25N5O2Cor e Forma:SolidPeso molecular:367.44JAK2-IN-11
CAS:JAK2-IN-11 is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Fórmula:C31H31F3N8O4Cor e Forma:SolidPeso molecular:639.64JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Cor e Forma:SolidJNK-IN-17
CAS:JNK-IN-17 (Compound 9J) is a selective and potent inhibitor of JNK, exhibiting IC50 values of 0.039 μM for JNK1 and 0.079 μM for JNK3. It effectively inhibits c-Jun phosphorylation in Streptozotocin-induced INS-1 pancreatic β cells, with an IC50 of 0.082 μM. JNK-IN-17 shows inhibition rates of ≤ 33% for the four major P450 isoforms (2C9, 2D6, 3A4, 1A2) in human liver microsomes, indicating a relatively low risk of drug interactions. This compound can be utilized in research on neurological and metabolic disorders, including Parkinson's disease.Fórmula:C28H23N9OPeso molecular:501.55
